FSHD affects over 25,000 individuals in the United States. It is the third most common muscular dystrophy by incidence but may be the most common by prevalence (Orphanet, 2008). The disease is thought to be caused by a combination of chromatin changes that cause expression of the DUX4 gene, together with stabilization of the DUX4 transcript by an allele-specific polyA signal. Pharmacological inhibition of DUX4 activity is an attractive approach to developing a therapy for FSHD. We have shown that DUX4 causes cell death of C2C12 myoblasts, used this assay to screen 200,000 compounds for inhibitors of DUX4, performed a number of secondary screens, and identified approximately 640 verified hits. From this set, we propose to identify those compounds with the highest likelihood of being developed into drugs. We will begin preliminary preclinical development by synthesizing key compounds and related derivatives, and screening these for activity on DUX4-expressing cells. We will test the most promising of these in mouse models based on conditional expression of DUX4.
We aim to identify 1-3 chemical series suitable for continued development into drugs for the treatment of FSHD.

Public Health Relevance

FSHD affects over 25,000 people in the United States. There is currently no treatment for this devastating muscular dystrophy. The disease has recently been linked to the gene DUX4, which encodes a protein that is toxic to muscle progenitor cells. We have screened a chemical library of 200,000 compounds and identified 640 compounds with a protective effect on cells expressing DUX4. We propose to identify within this set, those compounds with the highest likelihood of being developed into drugs that can block DUX4. We will begin preliminary preclinical development by synthesizing key compounds and related derivatives, and screening these for activity on DUX4-expressing cells. We will test the most promising of these in mice that carry the DUX4 gene, evaluating their ability to prevent damage caused by DUX4 expression. The goal is to identify compounds suitable for development into drugs for the treatment of FSHD.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21NS076671-02
Application #
8338453
Study Section
National Institute of Neurological Disorders and Stroke Initial Review Group (NSD)
Program Officer
Porter, John D
Project Start
2011-09-30
Project End
2013-08-31
Budget Start
2012-09-01
Budget End
2013-08-31
Support Year
2
Fiscal Year
2012
Total Cost
$264,250
Indirect Cost
$89,250
Name
University of Minnesota Twin Cities
Department
Pediatrics
Type
Schools of Medicine
DUNS #
555917996
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Borges, Luciene; Iacovino, Michelina; Mayerhofer, Timothy et al. (2012) A critical role for endoglin in the emergence of blood during embryonic development. Blood 119:5417-28